Not only did a majority of each group say they hadn’t heard of biosimilars, but those who had heard of them had negative perceptions. The study assessed perspectives among patients aged 11 to 21 years ...

Rheumatologist Marcus Snow, MD, is comfortable with prescribing biosimilars as a first-line, first-time biologic, and discussing them with patients. "If a biosimilar is on the market, it has gone ...

Providers and patients who want to understand biosimilars can now navigate through a new web app, that was created by Prime, and delivered in partnership with the AMCP Foundation and Biosimilars ...

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options. Ryan Haumschild, PharmD, MS, MBA: Speaking ...

Biosimilars are driving down drug costs, expanding access to critical treatments, and creating space for future innovation. In this episode, Linda Choi MacDonald, EVP and Global Head of Commercial at ...

Two bipartisan bills aimed at clarifying what constitutes a new chemical entity (NCE) and providing education on biosimilars to consumers and physicians were signed into law by President Joe Biden on ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can ...

Sen. Rand Paul's (R–Ky.) proposed Expedited Access to Biosimilars Act was unanimously voted out of the Senate Health, ...

ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Janet Woodcock, the acting commissioner of the US Food and Drug Administration (FDA), says there has been a “significant increase” in biosimilars approvals as the pharmaceutical industry has shown ...

On July 22, 2026, the U.S. Senate Committee on Health, Education, Labor and Pensions (“HELP”) voted to advance the Expedited Access to Biosimilars ...